DANA-FARBER CANCER INSTITUTE

Adjuvant olaparib showed continued efficacy in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients, with reduced recurrence rates and improved survival rates compared to placebo, according to the OlympiA trial's third analysis.

Patients with low-risk DCIS under active monitoring reported comparable physical, emotional, and psychological outcomes to those receiving upfront treatment, according to the COMET trial presented at SABCS 2024. Published in JAMA Oncology, the study found no significant differences in quality of life, anxiety, or worry about DCIS between the two groups, though there was a trend toward higher depression scores in the guideline-concordant care arm. Active monitoring showed no markedly negative impact on patients’ quality of life in the short term.

Orserdu showed similar or slightly higher time to treatment discontinuation and next treatment in HR-positive, HER2-negative advanced breast cancer with ESR1 mutation compared to EMERALD trial PFS. Real-world median time to next treatment was 6.43 months and to discontinuation was 4.6 months. Patients with PI3K pathway alterations had worse outcomes.

The PATINA trial results show palbociclib (IBRANCE®) plus standard-of-care maintenance therapy significantly improves progression-free survival in HR+, HER2+ metastatic breast cancer patients, extending median PFS by over 15 months. The study, sponsored by Alliance Foundation Trials, is the first large phase III to demonstrate CDK4/6 inhibition benefits in this patient group. Pfizer plans to discuss these results with regulatory authorities.

Women with low-risk ductal carcinoma in-situ (DCIS) report similar quality of life whether under active monitoring or surgery after two years. The COMET study, led by Dana-Farber Cancer Institute and Duke Cancer Institute, found comparable health-related quality of life, anxiety, depression, worries, and symptom trajectories between the two groups. The study suggests active monitoring as a reasonable short-term approach for low-risk DCIS.

LYNPARZA (olaparib) showed sustained improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, reducing death risk by 28% vs. placebo. 87.5% of LYNPARZA patients were alive at six years vs. 83.2% in the placebo group.

The OlympiA trial's 6-year analysis showed olaparib's efficacy in reducing recurrences and deaths in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients, with consistent benefits across subgroups. The FDA approved olaparib for this use based on initial trial data.

Elacestrant showed slightly higher time to next treatment and discontinuation vs PFS in HR+/HER2–, ESR1-mutant breast cancer patients in a phase 3 trial. Patients with PI3K pathway alterations had worse outcomes.

Anne Sophie Michallet discusses ERADIC trial results comparing MRD-guided therapy with ibrutinib and venetoclax vs standard combination in intermediate-risk CLL, emphasizing defining best patient profile due to potential cardiologic toxicity.

Kisqali (ribociclib) in combination with endocrine therapy showed a 28.5% reduction in distant recurrence in HR+/HER2- early breast cancer patients, with benefits extending beyond 3-year treatment. Data presented at SABCS reinforced the importance of adding CDK4/6 inhibitors to endocrine therapy for high-risk patients, regardless of nodal status.